| Date | Title | Description |
| 14.12.2025 | Disney Invests in OpenAI, Tech Stocks Wobble Amid AI Concerns | Disney announced a $1 billion investment in OpenAI, granting access to its characters for AI-generated content. This move coincides with a market shift as investors reassess the AI boom, triggered by Oracle’s disappointing earnings. While t... |
| 10.12.2025 | S&P 500, Dow close at record highs as Oracle sparks rush out of AI trade into broader market | The Dow Jones Industrial Average and S&P 500 reached new heights on Thursday, as a Federal Reserve interest rate cut followed by disappointing Oracle results prompted investors to move out of high-flying tech stocks and into names that ... |
| 13.01.2025 | Kardigan: $300 Million Raised For Modernizing Cardiovascular Drug Development | Kardigan – a heart health company modernizing cardiovascular drug development – announced it launched with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they ... |
| 01.04.2024 | Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing | - |
| 11.03.2024 | Rhythm Pharmaceuticals Announces New Employment Inducement Grants | - |
| 11.03.2024 | Rhythm Pharmaceuticals Announces New Employment Inducement Grants | BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, ... |
| 06.03.2024 | Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences | - |
| 06.03.2023 | Rhythm Pharmaceuticals Acquires Xinvento | Rhythm Pharmaceuticals, a Boston, MA-based commercial-stage biopharmaceutical company, acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).
According to the terms of th... |
| 03.11.2022 | Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek® | /EIN News/ -- -- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in children with BBS showed a significant positive correlation between degree of hyperphagia and body mass index (BMI) --
-- 84% of patients with BB... |
| 19.09.2022 | Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering | BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and sev... |
| 12.07.2022 | Flagship unwraps new AI biotech that looks to predict variants before they’re here | While Moderna is testing Omicron-specific boosters for this fall, its investor Flagship Pioneering is building a biotech that says it uses AI to predict virus variants prior to outbreaks.
Apriori Bio, derived from the La... |
| 12.07.2022 | 'Approvability has been put to bed': Aldeyra says eye drop clears three dry eye signals en route to FDA | Aldeyra’s attempt at treating dry eye disease has seen a few ups and downs in recent years, but the biotech’s sight to approval got a little clearer Tuesday with a crossover trial success that will pad its case to the FDA this qua... |
| 12.07.2022 | Jubilant HollisterStier pumps $77M into Montreal facility to double its capacity | Following a second FDA OK for its genetic obesity drug last month for patients with Bardet-Biedl syndrome, Rhythm Pharmaceuticals continues its quest to expand the indication for its drug Imcivree.
The Boston-based biotech dropped interim P... |
| 12.07.2022 | Jubilant HollisterStier pumps $77M into Montreal facility to double its capacity | Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major milestone for the next-gen gene editing technique known as base editing.
Now officially in a Phase Ib clinical trial in New Zealand, VERVE-101... |
| 13.01.2022 | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder | Lund, Sweden - 13 January 2022 - Camurus (NASDAQ STO: CAMX) today announces that the company's license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in pati... |
| 13.01.2022 | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder Thu, Jan 13, 2022 16:30 CET
Lund, Sweden — 13 January 2022 — Camurus (NASDAQ STO: CAMX) today announces that the company’s... |
| 02.11.2021 | Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results - Form 8-K | Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
-- U.S. and EU regulatory filings submitted for IMCIVREE® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway --
-- Delivered ... |
| 02.11.2021 | Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results | -- U.S. and EU regulatory filings submitted for IMCIVREE® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway --
-- Delivered a total of 22 presentations at three major medical conferences --
--... |
| 14.10.2021 | Rhythm Pharmaceuticals : Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program | -- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger --
-- Updated results from Uncovering Rare Obesity® testing prog... |
| 22.09.2021 | Rhythm Pharmaceuticals : Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting | -- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome --
-- Efficacy results from complete to... |
| 03.08.2021 | Rhythm Pharmaceuticals : Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity | -- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities --
-- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics... |
| 10.02.2021 | Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares | BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the ... |
| 07.01.2020 | Rhythm CEO Keith Gottesdiener hits the exit; Takeda sets up an AI discovery program at MIT | → Rhythm Pharmaceuticals $RYTM CEO Keith Gottesdiener is planning to stay at the helm until the biotech completes its new drug application, and then head out. He says it’s the right time to hand over the reins and the company... |
| 08.11.2019 | With key test still looming, Celgene and Acceleron nab FDA okay for beta-thalassemia med | While pricing concerns continue to cloud the future of bluebird bio’s gene therapy fix, the FDA has given its okay for Celgene and Acceleron’s beta-thalassemia drug Reblozyl — to treat anemia in adults who require regular ... |
| 10.11.2017 | Novartis makes its case on why RTH258 can grab a blockbuster piece of Regeneron's AMD market | Vasant Narasimhan, Novartis’ CEO-designate Bloomberg
Soon-to-be Novartis $NVS CEO Vas Narasimhan has peeled back the cover on more detailed Phase III data for their blockbuster Eylea rival RTH258 (brolucizumab), explaining w... |
| 06.10.2017 | Term Sheet — Friday, October 6 | DAYS OF CHANGE
Happy Friday, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
In an effort to woo drivers, Uber launched an initiative called, 180 Days of Change — a campaign that aims to make “meaningful c... |
| 06.09.2017 | Term Sheet — Wednesday, September 6 | SHOPPING SPREE
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
The deal, which is pending approval from the NBA Board of Governors, began in July. Fertitta who has been a lifelon... |
| 24.08.2017 | AstraZeneca researchers plumb positive data to back extended use of Brilinta | After suffering back-to-back clinical failures last year that forced AstraZeneca to finally back off its projection of a brilliant megablockbuster future for Brilinta, the struggling pharma giant has come up with a posi... |
| 17.02.2017 | Term Sheet — Friday, February 17 | IT’s TIME TO TAKE AI SERIOUSLY
The following is from the latest print edition of Fortune, where I write a regular column about technology and startups called “💥Boom with a View💥.”
Paid Content You can't secure what you can't see From ExtraH... |
| 17.02.2017 | NEA Leads $41M Round For Rhythm | Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic disorders, today announced the completion of a $41 million mezzanine round of financing with existin... |
| 16.02.2017 | Rhythm Closes $41M Mezzanine Financing | Rhythm, a Boston, MA-based biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic disorders, completed a $41m mezzanine round of financing.
Backers included existing... |
| 16.02.2017 | Rhythm Completes $41 Million Mezzanine Financing | Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic disorders, today announced the completion of a $41 million mezzanine round of financing with existin... |
| 07.07.2016 | KaloBios binds up Martin Shkreli and cages his stock in a long goodbye | The new CEO at KaloBios has already made it clear that he doesn’t want to see Martin Shkreli playing new games with the company’s stock. Now, just to make sure that can never happen, he’s provided some legal rope and duct tape t... |
| 13.08.2015 | Daily funding roundup - August 13, 2015 | Massdrop landed $40M; View raised $150M; DispatchHealth secured $3.6M
Massdrop raised a $40 million Series B financing round led by August Capital with continued support from First Round Capital, Mayfield Fund, and Cowboy Ventures. The comp... |
| 13.08.2015 | Rhythm Completes $40M Series A Financing | Rhythm, a Boston, Massachusetts-based biopharmaceutical company developing peptide therapeutics that address unmet needs in gastrointestinal diseases and obesity, completed a $40m Series A financing.
New investors OrbiMed, Deerfield Managem... |
| 28.08.2014 | Rhythm Files for IPO | Rhythm, a Boston, Mass.-based biopharmaceutical company developing peptide therapeutics that address gastrointestinal diseases and genetic deficiencies that result in metabolic disorders, filed a registration statement with the U.S. Securit... |
| 27.11.2012 | Rhythm Closes Additional $8M in Series B Financing | Rhythm, a Boston, MA-based biotechnology company, has closed on an additional $8m in Series B financing.
Pfizer Venture Investments, the venture capital arm of Pfizer, has joined existing investors MPM Capital, New Enterprise Associates, Th... |
| 13.06.2012 | Rhythm Raises $25M in Series B Financing | Rhythm, a Boston, Massachusetts-based biotechnology company developing peptide therapeutics that address needs in metabolic diseases, has raised $25m in Series B financing.
Backers include all existing investors MPM Capital (MPM), New Enter... |
| 15.09.2010 | Third Rock raises $426 million, opens in San Fran | Boston investment firm Third Rock Ventures LLC has raised $426 million for its second (oversubscribed) fund and is opening a San Francisco office to continue its practice of "launching and supporting transformative life sciences compan... |
| 14.09.2010 | Third Rock Ventures raises $426M, opens West Coast office | Founded in 2007 with a $378 million fund, Third Rock has invested in 15 life sciences companies, including Constellation Pharmaceuticals (gene-repair therapies), Agios Pharmaceuticals (cancer metabolism) and Zafgen (obesity therapies). The ... |
| 08.09.2010 | Rhythm Completes $40M Series A Financing Round | Rhythm, a Boston, Massachusetts-based biotechnology company developing peptide therapeutics for metabolic diseases, has completed its Series A financing, raising additional $19m in a second closing of the round.
Third Rock Ventures (TRV) jo... |
| 29.03.2010 | Morning Read: VC dollars are chasing obesity | Boston-based Rhythm Pharmaceuticals, which raised $21 million in a Series A round for treatments for metabolic diseases based on hormones that introduce changes to a cell’s metabolism.
ValenTX, of Carpinteria, Calif., raised $22 million to ... |
| - | Morning Read: VC dollars are chasing obesity | Highlights of the important and the interesting from the world of healthcare:
VC dollars are chasing obesity: Startups focused on a variety of disorders brought on by obesity having been cashing in with venture capitalists lately, Reuters r... |
| - | Third Rock Ventures raises $426M, opens West Coast office | Boston investment firm Third Rock Ventures LLC has raised $426 million for its second (oversubscribed) fund and is opening a San Francisco office to continue its practice of “launching and supporting transformative life sciences companies.”... |
